CFTR gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles
Mark A. Phillips, Lei Lei, Katarina Kulhankova, María Cristina Gingerich, Laura Marquez Loza, Amber Vu, Biao He, Ian M. Thornell, Paul B. McCray · 2026
Read CFTR gene delivery to human airway epithelia using parainfluenza virus 5 amplifying virus-like particles by Mark A. Phillips, Lei Lei, Katarina Kulhankova, María Cristina Gingerich, Laura Marquez Loza, Amber Vu, Biao He, Ian M. Thornell, Paul B. McCray (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13310626.txt.
Description
Mark A. Phillips and colleagues deliver the cystic fibrosis gene in 2026 to human airway cells using particles derived from parainfluenza virus 5. The particles carried either a marker gene or a corrected copy of CFTR, the chloride channel gene broken in cystic fibrosis. Tests used primary airway cell cultures grown from both healthy and cystic fibrosis donors.
Applied to the airway surface, the particles mainly entered ciliated cells, with lesser entry into secretory and basal cells. Marker expression faded gradually over a month. Correcting roughly fifteen percent of cystic fibrosis cells restored channel-driven electrical current to healthy levels. At least a tenth of patients cannot use current modulator drugs, leaving gene delivery their main hope. The authors present the viral particle platform as a flexible carrier for respiratory gene cargoes. Persistence and repeat dosing remain the open questions.
Catalog record
| CREATOR | Mark A. Phillips, Lei Lei, Katarina Kulhankova, María Cristina Gingerich, Laura Marquez Loza, Amber Vu, Biao He, Ian M. Thornell, Paul B. McCray |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |